Healthcare
Zydus Lifesciences Limited (zyduslife) Receives EIR from USFDA for Injectable Facility with VAI Classification
Zydus Lifesciences Limited (ZYDUSLIFE) receives EIR from USFDA for its injectable facility with Voluntary Action Indicated (VAI) classification.
Zydus Lifesciences Limited (ZYDUSLIFE) has received the Establishment Inspection Report (EIR) from the USFDA for its injectable facility located at Zydus Biotech Park, Ahmedabad, with Voluntary Action Indicated (VAI) classification. The GMP surveillance inspection was conducted from 27th April to 5th May 2026. This development signifies a significant milestone for the company as it underscores the compliance and quality standards of its manufacturing processes. The Voluntary Action Indicated classification indicates that the USFDA has identified areas for improvement but does not pose an immediate threat to public health.
Regulatory Milestone
This EIR marks an important regulatory milestone for Zydus Lifesciences Limited, reflecting the company’s commitment to maintaining high standards in its manufacturing operations. The Voluntary Action Indicated classification is a positive step forward, as it demonstrates the company’s proactive approach to addressing any identified areas for improvement.
Quality Assurance
The successful completion of the GMP surveillance inspection and the receipt of the EIR from the USFDA highlight Zydus Lifesciences Limited’s dedication to quality assurance and regulatory compliance. The company will continue to work closely with the USFDA to ensure that all necessary actions are taken to address any identified areas for improvement, thereby maintaining the highest standards of product quality and safety.
As a result, Zydus Lifesciences Limited can confidently move forward with its plans to expand its injectable facility and enhance its manufacturing capabilities. This achievement will also likely bolster investor confidence and contribute to the company’s long-term growth and success.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Zydus Lifesciences Limited
Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Zydus gains 26.3% over three months and trades near its 52-week highs. The PEG of 0.61 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 84% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 16.5%, profits at 37.0%, and the PEG sits at 0.61 — below its growth rate. That combination is rare. Check Fundamentals of Zydus Lifesciences Limited.
Healthcare
Rainbow Childrens Medicare Limited (rainbow) Q2fy27 Earnings Update: Revenue Up 23%, PAT Rises 11%
Rainbow Childrens Medicare Limited (RAINBOW) reports Q2FY27 earnings with a 23% revenue increase and an 11% rise in PAT.
Rainbow Childrens Medicare Limited (RAINBOW) has announced its Q2FY27 earnings, showcasing a robust performance with a 23% increase in revenue and an 11% rise in PAT. The focus keyword, ‘Rainbow Childrens Medicare Limited RAINBOW Q2FY27 Earnings,’ encapsulates the essence of this financial update.
Operational Highlights
The company’s operational KPIs reflect significant growth. Notably, the number of IP discharges increased by 19% in Q2FY27 compared to the same period last year. Additionally, the occupancy rate saw a 10% rise, indicating higher utilization of hospital capacity. The average revenue per occupied bed (ARPOB) remained stable, underscoring efficient cost management.
Financial Performance
In terms of financial performance, Rainbow Childrens Medicare Limited’s EBITDA grew by 14% year-on-year, driven by strong operational efficiencies and strategic expansions. The EBITDA margin improved slightly, reflecting better cost control and operational leverage.
Forward-Looking Statement
Looking ahead, Rainbow Childrens Medicare Limited remains optimistic about its growth trajectory, with plans for further expansion and capacity enhancement in its existing and new hospitals. The company is committed to maintaining its high standards of healthcare delivery while exploring new avenues for growth and innovation.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Rainbow Childrens Medicare Limited
Rainbow Childrens Medicare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Rainbow falls 16.4% over three months and has not found a floor yet. The PEG stands at 4.58 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 31% of its 52-week range with RSI at 34. In other words, neither side has a clear edge right now. Revenue grows at 13.1% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Rainbow Childrens Medicare Limited.
Healthcare
Narayana Hrudayalaya Ltd. (NH) Q2 FY27 Results: Consolidated Revenue Up 73.0% Yoy
Narayana Hrudayalaya Ltd. announces Q2 FY27 results with consolidated revenue up 73.0% YoY and EBITDA up 42.0% YoY.
Narayana Hrudayalaya Limited, a leading healthcare service provider, announced its financial results for the second quarter (Q2 FY27) ended September 30th, 2026. The company reported consolidated operating revenue of ₹ 28,440 Mn, marking a year-on-year growth of 73.0%. The earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹ 6,054 Mn, up 42.0% YoY.
Strong Earnings Growth
The consolidated EBITDA rose 42.0% year-on-year and 19.8% quarter-on-quarter to ₹ 6,054 Mn, while the profit after tax (PAT) increased by 16.6% YoY and 45.3% QoQ to ₹ 3,012 Mn. Excluding the UK, revenue grew 22.6% YoY to ₹ 20,156 Mn and EBITDA grew 27.8% to ₹ 5,452 Mn, with the margin expanding to 27.0% from 25.9%.
India – Volume, Mix and Margin Expansion
India revenue grew 16.6% YoY, driven by higher patient volumes, complex procedures and a 75.7% rise in international patient revenue; India hospitals EBITDA margin expanded to 26.8% from 23.8% a year ago.
Forward-Looking Statement
With a strong first half behind us, we thank the investor community for their continued faith and remain confident of delivering on our expectations for the year, said Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Narayana Hrudayalaya Ltd.
Narayana Hrudayalaya Ltd. belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Narayana falls 15.3% over three months and has not found a floor yet. The PEG stands at 4.29 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 26% of its 52-week range with RSI at 38. In other words, neither side has a clear edge right now. Revenue grows at 20.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Narayana Hrudayalaya Ltd..
CORONA
Corona Remedies Limited (corona) Q2fy27: Revenue Up 22% Year-on-year
CORONA Remedies Limited (CORONA) reports highest ever revenue with 22% growth for Q2FY27 on Y-o-Y basis, outperforming IPM.
CORONA Remedies Limited (CORONA) has announced its unaudited financial results for the quarter and half year ended September 30, 2026, delivering the highest ever revenue with a growth of 22% year-on-year (Y-o-Y) basis. This impressive performance marks a significant milestone for the company, which continues to be one of the fastest growing companies among the top 30 Indian pharmaceutical companies.
Financial Performance
The financial performance snapshot reveals robust growth across key metrics. Revenue from operations stood at ₹441.2 crore for Q2FY27, a 22.2% increase compared to ₹361.1 crore in Q2FY26. EBITDA rose to ₹96.0 crore, up 22.3% from ₹78.5 crore in the same quarter last year. Profit After Tax (PAT) increased to ₹60.3 crore, reflecting a 15.3% growth from ₹52.3 crore in Q2FY26.
Key Business Highlights
CORONA Remedies Limited has demonstrated operational excellence and disciplined execution, leveraging all growth drivers to outperform the Indian Pharmaceutical Market (IPM). The company has now outpaced the IPM growth by 1.9 times as per MAT Sep’26. Additionally, CORONA has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad.
Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence, and investing in capabilities that will support our future growth.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of CORONA Remedies Limited
CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.
CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.
-
Credit Services3 days agoOnemi Technology Solutions Limited (kissht) Q2 FY27: AUM Surges 68% Yoy, Profitability Up 100%
-
Communication Services3 days agoOnmobile Global Limited (onmobile) Q2 FY27: Revenue Up 3.4% Qoq, Gaming Subscriber Base Grows 5.4%
-
ALIVUS2 days agoAlivus Life Sciences Limited (alivus) Q2fy27: Revenue Up 16.0% Yoy, Ebitda Margin at Record High
-
Banks - Regional2 days agoSuryoday Small Finance Bank Limited (suryoday) Q2 & H1 FY27: Profit After Tax Up 131%, Gross Advances Surge 34.6%
-
PINELABS2 days agoPine Labs Limited (pinelabs): Q2 FY27 Results: Revenue Growth Accelerates to 24% Yoy
-
GREAVESCOT2 days agoGreaves Cotton Limited Q2fy27: Revenue Up 44% Yoy, Ebitda Surges 43%
-
Industrials2 days agoPraj Industries Limited (prajind) Q2 FY27: Revenue Up 18%, PAT Rises 105%
-
Auto Parts3 days agoSchaeffler India Limited Q3cy26: Financial Highlights and Business Performance